The solution relates to the substance (15)-6,7-dimethoxy-l-[2-(4- trifluoromethylphenyl)ethyl]-l,2,3,4-tetrahydroisoquinoline of formula I, containing the desired S-enantiomer in an enantiomeric excess higher than or equal to 98.0%. Another solution is a manufacturing process for the present substance of formula I, which is synthesized via reduction of 6,7-dimethoxy-l-[2-(4- trifluoromethylphenyl)ethyl]-3,4-dihydroisoquinoline of formula II free base or hydrochloride using (R,R)-N-(p-toluenesulfonyl)- 1,2-diphenylethanediamine (chloro)(p-cymene)ruthenium(π) as a catalyst or using a catalyst generated in situ out of a ruthenium complex and a chiral ligand, wherein the catalyst used is in an amount lower than or equal to 2 molar %, related to the reduced substance (II).
该解决方案涉及式I的物质(15)-6,7-二甲
氧基-1-[2-(4-三
氟甲基苯基)乙基]-1,2,3,4-
四氢异喹啉,其中所含的所需S-对映体的对映体过量高于或等于98.0%。另一个解决方案是制造式I的现有物质的制造工艺,该工艺通过使用(R,R)-N-(对
甲苯磺酰基)-1,2-二
苯基
乙二胺(
氯)(
对二甲苯)
钌(π)作为
催化剂或使用由
钌配合物和手性
配体在原位生成的
催化剂,通过还原式II的自由碱基或
盐酸盐合成而来,其中所使用的
催化剂量低于或等于还原物(II)的2摩尔%。